Lori Wright is the CEO of Evolution Research Group, LLC and each of its 11 portfolio companies. ERG was formed in 2014 by merging Thievon-Wright Consulting Group, St. Louis Clinical Trials, Woodland International Research Group and Woodland Research Northwest. ERG immediately recapitalized, bringing on DFW Capital Partners, and became the platform for five additional acquisitions in 2017 and one in March 2018. On May 30, 2018 Linden Capital Partners, a health care private equity firm, announced it completed its acquisition of Evolution Research Group LLC. ERG remains focused on continuous quality improvement and exploring ways to better serve our research subjects and the pharmaceutical, biotechnology, and CRO industries. We are excited to partner with Linden who share our vision.
As CEO, Lori is responsible for the management of all clinical and business operations, the M&A strategy, execution and integration, and continues to manage several key client relationships. Currently, ERG is comprised of 11 fully-owned and operated clinical research units, a team of KOLs in various CNS indications, a consulting team and an affiliate network of 12 research sites. Th
Geographically dispersed, ERG’s site network is the largest, independent group in the US conducting Phase 1-2a inpatient, complex trials as well as late stage inpatient and outpatient trials in highly specialized populations.
Lori has been in the clinical research field for over 33 years and the majority has been in CNS drug development. She started her career while in college in the CRO space and, after 8 years, decided to pursue opportunities allowing direct patient interaction. As Director of Research, Finance and Administration at the Foundation for Depression and Manic Depression and Fieve Clinical Services, Lori participated in over 20 clinical trials managing the team of PIs, Sub-Investigators, CRCs, and the medical/clinical staff and participated as a rater in all trials. She developed the financial tracking system, recruitment and outreach programs, in addition to managing all business development activities.
Over the past 25 years, she has developed strong collaborative relationships with very high level professionals within the industry including pharmaceutical sponsors, CROs and biotechnology organizations. Working closely with her own employees and outside consultants, she has become a significant influence in the field of neuroscience research.